"de-risking" risk reduction: Should coronary artery calcium scoring be the gatekeeper to preventive pharmacotherapy with the polypill?

Journal of the American College of Cardiology

Volumn 63, Issue 5, 2014, Pages 444-446

  Wijns, William ^a   Rusinaru, Dan ^a  

^a Cardiovascular Research Centre   (Belgium)

Author keywords

polypill; risk stratification; subclinical atherosclerosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; STATIN (PROTEIN); THIAZIDE DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL CLASSIFICATION; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY CALCIUM SCORE; COST BENEFIT ANALYSIS; HEALTH CARE AVAILABILITY; HEALTH CARE PLANNING; HUMAN; NOTE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; POLYPHARMACY; POLYPILL; PREDICTION; PREDICTIVE VALUE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STANDARDIZATION; TREATMENT INDICATION; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; DRUG SAFETY; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; ISCHEMIC HEART DISEASE; PREVENTIVE PHARMACOTHERAPY; RADIOCARDIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

POLYPILL; RISK STRATIFICATION; SUBCLINICAL ATHEROSCLEROSIS;

ATHEROSCLEROSIS; CALCINOSIS; CALCIUM; CORONARY ARTERY DISEASE; CORONARY VESSELS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; RISK ASSESSMENT;

EID: 84893299678     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.044     Document Type: Editorial

References (14)

1. World Health Statistics 2013. Cardiovascular diseases. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed September 7, 2013.
2. S. Yusuf, S. Hawken, S. Ounpuu for the INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
3. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419 1424
4. S. Yusuf, P. Pais, and R. Afzal et al. Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
5. E. Lonn, J. Bosch, K.K. Teo, P. Pais, D. Xavier, and S. Yusuf The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions Circulation 122 2010 2078 2088
6. M.S. Bittencourt, M.J. Blaha, and R. Blankstein et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events - implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol 63 2014 434 443
7. P. Greenland, J.S. Alpert, and G.A. Beller et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 e103
8. T.S. Polonsky, R.L. McClelland, and N.W. Jorgensen et al. Coronary artery calcium score and risk classification for coronary heart disease prediction JAMA 303 2010 1610 1616
9. K. Nasir, J. Rubin, and M.J. Blaha et al. Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals Circ Cardiovasc Imaging 5 2012 467 473
10. J.K. Min, A. Dunning, and F.Y. Lin et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease J Am Coll Cardiol 58 2011 849 860
11. S. Thom, N. Poulter, and J. Field et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. The UMPIRE randomized clinical trial JAMA 310 2013 918 929
12. Heart Outcomes Prevention Evaluation-3 (HOPE-3). Available at: http://clinicaltrials.gov/show/NCT00468923. Accessed September 7, 2013.
13. S.K. Virdee, S.M. Greenfield, K. Fletcher, R.J. McManus, F.D. Hobbs, and J. Mant Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study BMJ Open 3 2013 e002498
14. A. Rodgers, A. Patel, O. Berwanger for the PILL Collaborative Group An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6 2011 e19857